Physician profile
Robert A Pohlmeyer
NPI 1396782702
$1,616.06
in general payments reported to CMS, 2019-2025
31 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $35.55 · 2021: $11.92 · 2022: $182 · 2023: $233 · 2024: $440 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $171.16 | 2019-2025 | Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $126.56 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $114.83 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Genentech USA, INC. | $105.69 | 2019-2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Takeda Pharmaceuticals U.S.A., INC. | $98.32 | 2023-2025 | Iclusig, Ninlaro |
| Gilead Sciences, INC. | $92.04 | 2021-2025 | Trodelvy |
| Seagen INC. | $79.50 | 2022-2023 | Padcev, Tukysa |
| Array Biopharma INC | $72.64 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Astrazeneca Pharmaceuticals Lp | $64.88 | 2019-2025 | Tagrisso |
| Pfizer INC. | $62.90 | 2019-2025 | |
| Eisai INC. | $62.02 | 2022-2024 | |
| Daiichi Sankyo INC. | $58.78 | 2019-2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $49.20 | 2023-2024 | Libtayo |
| Celgene Corporation | $48.17 | 2022-2025 | Reblozyl |
| Jazz Pharmaceuticals INC. | $35.46 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.91 | 2022 | |
| Abbvie INC. | $32.50 | 2025 | |
| Aveo Pharmaceuticals, INC. | $28.54 | 2025 | |
| Geron Corporation | $28.09 | 2025 | Rytelo |
| Kyowa Kirin, INC. | $27.94 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $26.11 | 2019-2023 | Opdivo |
| Stemline Therapeutics INC. | $25.12 | 2024 | Elzonris |
| Servier Pharmaceuticals LLC | $23.54 | 2023 | |
| Beigene USA, INC. | $22.69 | 2023 | Brukinsa |
| Exelixis INC. | $21.75 | 2024 | Cabometyx |
| Mirati Therapeutics, INC. | $18.67 | 2024 | Krazati |
| Tersera Therapeutics LLC | $18.50 | 2025 | Xermelo |
| Lilly USA, LLC | $18.44 | 2025 | Jaypirca, Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $16.45 | 2019 | |
| Glaxosmithkline, LLC. | $16.39 | 2024 | Ojjaara |
| Beone Medicines USA, INC. | $16.27 | 2025 | Brukinsa, Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pohlmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.